#USA #New York #Rosen Law Firm #Soleno Therapeutics #SLNO

Rosen Law Firm's Investigation Into Soleno Therapeutics, Inc.

The Rosen Law Firm, a prominent investor rights law firm, is urging shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) to explore their rights in light of potential securities class action claims. This investigation comes after concerns were raised regarding the accuracy of business information disseminated by the company, which may have misled investors and impacted stock performance.

Background of the Investigation

On August 15, 2025, a report published by Investing.com detailed a significant decline in Soleno Therapeutics' stock value following a short report by Scorpion Capital. The short report voiced severe concerns regarding the company's recently approved treatment for Prader-Willi syndrome, known as VYKAT XR. It suggested that the drug might face safety issues and could either be withdrawn from the market or see a notable drop in new prescriptions.

As a direct consequence, shares of Soleno Therapeutics dropped by 7.4% that day, followed by an additional decline of 4.9% on the subsequent trading session. These events have raised alarms among investors who may not have been aware of the underlying risks associated with the company's operations and news.

How Investors Can Participate

For investors who have acquired Soleno Therapeutics securities, there might be an avenue to seek compensation without incurring any out-of-pocket expenses, thanks to a contingency fee structure. The Rosen Law Firm is committed to building a class action aimed at recovering losses suffered by investors. Those interested in this potential class action are encouraged to submit their information online or to contact the firm directly via phone or email for further details.

Importance of Qualified Legal Counsel

In light of this situation, Rosen Law Firm emphasizes the importance of selecting qualified legal representation. Not all firms possess the necessary experience or resources to lead effectively in such significant legal matters. The Rosen Law Firm has a distinguished track record of success, including the largest settlement ever in a securities class action against a Chinese company, and has consistently ranked at the top for its number of settlements and recoveries on behalf of investors.

Their commitment to investors is reflected in their notable recovery achievements, which include over $438 million for investors in just the year 2019. Their firm is well-regarded, with recognition from prestigious legal rankings like Lawdragon and Super Lawyers, exemplifying their capability to handle complex securities fraud cases.

Moving Forward

As more inquiries and participation in the class action develop, the Rosen Law Firm will continue to keep the public informed through various media platforms, including LinkedIn, Twitter, and Facebook. They encourage all affected Soleno Therapeutics investors to act promptly and inform themselves of their rights and potential remedies available to them as part of this investigation.

For more information on the Rosen Law Firm and the investigation into Soleno Therapeutics, or to express interest in the class action, visit rosenlegal.com or reach out directly. Investors are encouraged to stay informed and aware of their rights as this situation unfolds.

In conclusion, if you are a shareholder of Soleno Therapeutics, it is paramount to assess your position regarding these allegations and consider joining the class action led by the Rosen Law Firm. This proactive approach could potentially lead to significant financial recuperation for those affected by the recent downturn in the company’s stock due to misleading business practices.